Risk of new primary nonbreast cancers after breast cancer treatment: A dutch population-based study

Journal of Clinical Oncology

Volumn 26, Issue 8, 2008, Pages 1239-1246

  Schaapveld, Michael ^a   Visser, Otto ^a   Louwman, Marieke J ^a   De Vries, Elisabeth G E ^a   Willemse, Pax H B ^a   Otter, Reneé ^a   Van Der Graaf, Winette T A ^a   Coebergh, Jan Willem W ^a   Van Leeuwen, Flora E ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CANCER SURVIVOR; COLON CANCER; ESOPHAGUS CANCER; FEMALE; HUMAN; KIDNEY CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MASTECTOMY; MELANOMA; NETHERLANDS; NONHODGKIN LYMPHOMA; OVARY CANCER; PRIORITY JOURNAL; RECTUM CANCER; RISK ASSESSMENT; RISK FACTOR; SECOND CANCER; SOFT TISSUE SARCOMA; STOMACH CANCER; UTERUS CANCER; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CLINICAL TRIAL; COHORT ANALYSIS; FOLLOW UP; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; NETHERLANDS; RISK FACTORS; SURVIVAL RATE;

EID: 41649085804     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.9081     Document Type: Article

References (50)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2:533-543, 2001
2. Sant M, Capocaccia R, Coleman MP, et al: EUROCARE Working Group. Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer 37:1659-1667, 2001
3. Clegg LX, Li FP, Hankey BF, et al: Cancer survival among US whites and minorities: A SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med 162:1985-1993, 2002
4. Harvey EB, Brinton LA: Second cancer following cancer of the breast in Connecticut, 1935-82. Natl Cancer Inst Monogr 68:99-112, 1985
5. Storm HH, Jensen OM: Risk of contralateral breast cancer in Denmark 1943-80. Br J Cancer 54:483-492, 1986
6. Cook LS, White E, Schwartz SM, et al: A population-based study of contralateral breast cancer following a first primary breast cancer. Cancer Causes Control 7:382-390, 1996
7. Volk N, Pompe-Kirn V: Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control 8:764-770, 1997
8. Evans HS, Lewis CM, Robinson D, et al: Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England. Br J Cancer 84:435-440, 2001
9. Soerjomataram I, Louwman WJ, de Vries E, et al: Primary malignancy after primary female breast cancer in the South of the Netherlands, 1972-2001. Breast Cancer Res Treat 93:91-95, 2005
10. Ahsan H, Neugut AI: Radiation therapy for breast cancer and increased risk for esophageal carcinoma. Ann Intern Med 128:114-117, 1998
11. Neugut AI, Robinson E, Lee WC, et al: Lung cancer after radiation therapy for breast cancer. Cancer 71:3054-3057, 1993
12. Rubino C, de Valthaire F, Diallo I, et al: Increased risk of second cancers following breast cancer: Role of the initial treatment. Breast Cancer Res Treat 61:183-195, 2000
13. Huang J, Mackillop WJ: Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer 92:172-180, 2001
14. Cozen W, Bernstein L, Wang F, et al: The risk of angiosarcoma following primary breast cancer. Br J Cancer 81:532-836, 1999
15. Karlsson P, Holmberg E, Samuelsson A, et al: Soft tissue sarcoma after treatment for breast cancer: A Swedish population-based study. Eur J Cancer 34:2068-2075, 1998
16. Ewertz M, Mouridsen HT: Second cancer following cancer of the female breast in Denmark, 1943-82. Natl Cancer Inst Monogr 68:325-329, 1985
17. van Leeuwen FE, Benraadt J, Coebergh JW, et al: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448-452, 1994
18. Rutqvist LE, Johansson H, Signomklao T, et al: Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies: Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87:645-651, 1995
19. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
20. Bernstein L, Deapen D, Cerhan JR, et al: Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91:1654-1662, 1999
21. Bergman L, Beelen ML, Gallee MP, et al: Risk and prognosis of endometrial cancer after tamoxifen for breast cancer: Comprehensive Cancer Centres' ALERT Group - Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356:881-887, 2000
22. Diamandidou E, Buzdar AU, Smith TL, et al: Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas MD Anderson cancer center experience. J Clin Oncol 14:2722-2730, 1996
23. Smith RE, Bryant J, DeCillis A, et al: National Surgical Adjuvant Breast and Bowel Project Experience. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 21:1195-1204, 2003
24. Chaplain G, Milan C, Sgro C, et al: Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: A population-based study. J Clin Oncol 18:2836-2842, 2000
25. Gooley TA, Leisenring W, Crowley J, et al: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18:695-706, 1999
26. Choudhury JB: Non-parametric confidence interval estimation for competing risks analysis: Application to contraceptive data. Stat Med 21:1129-1144, 2002
27. Lunn M, McNeil D: Applying Cox regression to competing risks. Biometrics 51:524-532, 1995
28. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
29. Olson SH, Trevisan M, Marshall JR, et al: Body mass index, weight gain, and risk of endometrial cancer. Nutr Cancer 23:141-149, 1995
30. McPherson CP, Sellers TA, Potter JD, et al: Reproductive factors and risk of endometrial cancer: The Iowa Women's Health Study. Am J Epidemiol 143:1195-1202, 1996
31. Huang Z, Hankinson SE, Colditz GA, et al: Dual effects of weight and weight gain on breast cancer risk. JAMA 278:1407-1411, 1997
32. Lindblad P, Chow WH, Chan J, et al: The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 42:107-112, 1999
33. Kmet LM, Cook LS, Weiss NS, et al: Risk factors for colorectal cancer following breast cancer. Breast Cancer Res Treat 79:143-147, 2003
34. Anderson KE, Anderson E, Mink PJ, et al: Diabetes and endometrial cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 10:611-616, 2001
35. Frank TS, Manley SA, Olopade OI, et al: Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16:2417-2425, 1998
36. Peto J, Collins N, Barfoot R, et al: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943-949, 1999
37. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases: Anglian Breast Cancer Study Group. Br J Cancer 83:1301-1308, 2000
38. Swerdlow AJ, Storm HH, Sasieni PD: Risks of second primary malignancy in patients with cutaneous and ocular melanoma in Denmark, 1943-1989. Int J Cancer 61:773-779, 1995
39. Wassberg C, Thorn M, Yuen J, et al: Second primary cancers in patients with cutaneous malignant melanoma: A population-based study in Sweden. Br J Cancer 73:255-259, 1996
40. Holly EA, Cress RD, Ahn DK: Cutaneous melanoma in women. III. Reproductive factors and oral contraceptive use. Am J Epidemiol 141:943-950, 1995
41. Smith MA, Fine JA, Barnhill RL, et al: Hormonal and reproductive influences and risk of melanoma in women. Int J Epidemiol 27:751-757, 1998
42. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans: Overall Evaluations of Carcinogenicity - An Updating of IARC Monographs Volumes 1-42, Supplement 7. Lyon, France, IARC, 1987
43. Haas JF, Kittelmann B, Mehnert WH, et al: Risk of leukemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br J Cancer 55:213-218, 1987
44. Valagussa P, Moliterni A, Terenziani M, et al: Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer. Ann Oncol 5:803-808, 1994
45. Tallman MS, Gray R, Bennett JM, et al: Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: The Eastern Cooperative Oncology Group experience. J Clin Oncol 13:1557-1563, 1995
46. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans: Ionizing Radiation, part 1 - X- and Gamma Radiation and Neutrons, Volume 75. Lyon, France, IARC, 2000
47. Boice JD Jr, Blettner M, Kleinerman RA, et al: Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst 79:1295-1311, 1987
48. Curtis RE, Boice JD Jr, Stovall M, et al: Relationship of leukemia risk to radiation dose following cancer of the uterine corpus. J Natl Cancer Inst 86:1315-1324, 1994
49. Curtis RE, Boice JD Jr, Stovall M, et al: Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326:1745-1751, 1992
50. Boivin JF, Hutchison GB, Evans FB, et al: Leukemia after radiotherapy for first primary cancers of various anatomic sites. Am J Epidemiol 123:993-1003, 1986